Showing results (141-150 of 170) with videos related to
Sort By:
Pageof 17
Dermatology and Therapy|June 18, 2021
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 TrialsChristopher Griffiths, Marjolein de Bruin-Weller, Mette Deleuran, et al.Acta Dermato-Venereologica|April 21, 2023
The Treat-to-Target Project in Atopic Dermatitis: One Year OnMarjolein De Bruin-Weller, Mette Deleuran, Tilo Biedermann, et al.The Journal of Dermatological Treatment|June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trialsNeil J Korman, Richard B Warren, Jerry Bagel, et al.The Australasian Journal of Dermatology|May 14, 2024
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Considerations for paediatric patientsPeter Foley, Patrick D Mahar, Saxon D Smith, et al.The Journal of Clinical Endocrinology and Metabolism|December 9, 2014
Diagnosis of Graves' orbitopathy (DiaGO): results of a pilot study to assess the utility of an office tool for practicing endocrinologistsAnna L Mitchell, Linda Goss, Lemonia Mathiopoulou, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.The British Journal of Dermatology|August 10, 2023
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD studyJoseph F Merola, Albert S Chiou, Emmanuel During, et al.Lancet (London, England)|August 12, 2018
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trialsKenneth B Gordon, Bruce Strober, Mark Lebwohl, et al.Frontiers in Neurology|September 30, 2021
Study Protocol for the Development of a European eHealth Platform to Improve Quality of Life in Individuals With Huntington's Disease and Their Partners (HD-eHelp Study): A User-Centered Design ApproachPearl J C van Lonkhuizen, Niko J H Vegt, Eline Meijer, et al.Dermatology and Therapy|June 17, 2026
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment AdherenceJonathan I Silverberg, Alan D Irvine, Peter Foley, et al.Pageof 17